A model of chronic lung allograft rejection in the rat

European Respiratory Journal

Volumn 35, Issue 6, 2010, Pages 1354-1363

  Jungraithmayr, W ^a,b   Vogt, P ^a   Inci, I ^a   Hillinger, S ^a   Arni, S ^a   Korom, S ^a   Weder, W ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Bronchiolitis obliterans; Chronic rejection; Orthotopic rat lung transplantation; Rapamycin; Sensitisation

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CHEMOKINE RECEPTOR CXCR5; CYCLOSPORIN A; CYTOKINE; MESSENGER RNA; RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHIOLE; BRONCHIOLITIS OBLITERANS; BROWN NORWAY RAT; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DRUG DOSE INCREASE; EXPERIMENTAL STUDY; GENE EXPRESSION; GRAFT RECIPIENT; HELPER CELL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTERVENTION STUDY; LEWIS RAT; LUNG FIBROSIS; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MALE; NONHUMAN; ORGAN DONOR; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RESPIRATORY EPITHELIUM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN SENSITIZATION; THERAPY EFFECT; UPREGULATION;

ACTINS; ANIMALS; ANTIGENS, CD; ANTIGENS, CD3; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BRONCHIOLITIS OBLITERANS; CHEMOKINE CCL5; CHRONIC DISEASE; CYCLOSPORINE; DISEASE MODELS, ANIMAL; FLUORESCENT ANTIBODY TECHNIQUE; FORKHEAD TRANSCRIPTION FACTORS; GRAFT REJECTION; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; MACROPHAGES, ALVEOLAR; MALE; RATS; RATS, INBRED BN; RATS, INBRED LEW; SIROLIMUS; T-LYMPHOCYTES, HELPER-INDUCER; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, HOMOLOGOUS;

EID: 77953503910     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00110609     Document Type: Article

References (29)

1. Trulock EP, Christie JD, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth Official Adult Lung and Heart-Lung Transplantation Report-2007. J Heart Lung Transplant 2007; 26: 782-795.
2. Cramer DV, Qian SQ, Harnaha J, et al. Cardiac transplantation in the rat. I. The effect of histocompatibility differences on graft arteriosclerosis. Transplantation 1989; 47: 414-419.
3. Boehler A, Estenne M. Obliterative bronchiolitis after lung transplantation. Curr Opin Pulm Med 2000; 6: 133-139.
4. Valentine VG, Robbins RC, Berry GJ, et al. Actuarial survival of heart-lung and bilateral sequential lung transplant recipients with obliterative bronchiolitis. J Heart Lung Transplant 1996; 15: 371-383.
5. Hertz MI, Jessurun J, King MB, et al. Reproduction of the obliterative bronchiolitis lesion after heterotopic transplantation of mouse airways. Am J Pathol 1993; 142: 1945-1951.
6. Genden EM, Boros P, Liu J, et al. Orthotopic tracheal transplantation in the murine model. Transplantation 2002; 73: 1420-1425.
7. Sato M, Liu M, Anraku M, et al. Allograft airway fibrosis in the pulmonary milieu: a disorder of tissue remodeling. Am J Transplant 2008; 8: 517-528.
8. Matsumura Y, Marchevsky A, Zuo XJ, et al. Assessment of pathological changes associated with chronic allograft rejection and tolerance in two experimental models of rat lung transplantation. Transplantation 1995; 59: 1509-1517.
9. Lee AG, Wagner FM, Giaid A, et al. Immunohistochemical characterization of inflammatory and proliferative events during chronic rejection in rat lung allografts. Transplantation 1997; 64: 465-471.
10. Korom S, Hancock WW, Coito AJ, et al. Blockade of very late antigen-4 integrin binding to fibronectin in allograft recipients. II. Treatment with connecting segment-1 peptides prevents chronic rejection by attenuating arteriosclerotic development and suppressing intragraft T cell and macrophage activation. Transplantation 1998; 65: 854-859.
11. Stepkowski SM, Chen H, Daloze P, et al. Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney, and small bowel transplantation in the rat. Transplantation 1991; 51: 22-26.
12. Wasowska B, Wieder KJ, Hancock WW, et al. Cytokine and alloantibody networks in long term cardiac allografts in rat recipients treated with rapamycin. J Immunol 1996; 156: 395-404.
13. National Institutes of Health. Principles of Laboratory Animal Care. Publication No. 85-23, revised 1996. Bethesda, MD, National Institutes of Health, 1996.
14. Zhai W, Cardell M, De Meester I, et al. Intragraft DPP IV inhibition attenuates post-transplant pulmonary ischemia/reperfusion injury after extended ischemia. J Heart Lung Transplant 2007; 26: 174-180.
15. Graf R, Schiesser M, Lussi A, et al. Coordinate regulation of secretory stress proteins (PSP/reg, PAP I, PAP II, and PAP III) in the rat exocrine pancreas during experimental acute pancreatitis. J Surg Res 2002; 105: 136-144.
16. McDyer JF. Human and murine obliterative bronchiolitis in transplant. Proc Am Thorac Soc 2007; 4: 37-43.
17. Chen H, Wu J, Xu D, et al. Reversal of ongoing heart, kidney, and pancreas allograft rejection and suppression of accelerated heart allograft rejection in the rat by rapamycin. Transplantation 1993; 56: 661-666.
18. Belperio JA, Burdick MD, Keane MP, et al. The role of the CC chemokine, RANTES, in acute lung allograft rejection. J Immunol 2000; 165: 461-472.
19. Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007; 26: 1229-1242.
20. Ramirez AM, Shen Z, Ritzenthaler JD, et al. Myofibroblast transdifferentiation in obliterative bronchiolitis: TGF-β signaling through Smad3-dependent and -independent pathways. Am J Transplant 2006; 6: 2080-2088.
21. Pedagogos E, Hewitson TD, Walker RG, et al. Myofibroblast involvement in chronic transplant rejection. Transplantation 1997; 64: 1192-1197.
22. 2-terminal kinase-dependent pathway. Am J Respir Crit Care Med 2001; 163: 152-157.
23. Kupiec-Weglinski JW, Sablinski T, Hancock WW, et al. Modulation of accelerated rejection of cardiac allografts in sensitized rats by anti-interleukin 2 receptor monoclonal antibody and cyclosporine therapy. Transplantation 1991; 51: 300-305.
24. Meloni F, Vitulo P, Cascina A, et al. Bronchoalveolar lavage cytokine profile in a cohort of lung transplant recipients: a predictive role of interleukin-12 with respect to onset of bronchiolitis obliterans syndrome. J Heart Lung Transplant 2004; 23: 1053-1060.
25. Zhai Y, Ghobrial RM, Busuttil RW, et al. Th1 and Th2 cytokines in organ transplantation: paradigm lost? Crit Rev Immunol 1999; 19: 155-172.
26. Neuringer IP, Mannon RB, Coffman TM, et al. Immune cells in a mouse airway model of obliterative bronchiolitis. Am J Respir Cell Mol Biol 1998; 19: 379-386.
27. Sumitomo M, Sakiyama S, Tanida N, et al. Difference in cytokine production in acute and chronic rejection of rat lung allografts. Transpl Int 1996; 9: Suppl. 1, S223-S225.
28. Meloni F, Vitulo P, Bianco AM, et al. Regulatory CD4+CD25+ T cells in the peripheral blood of lung transplant recipients: correlation with transplant outcome. Transplantation 2004; 77: 762-766.
29. Jungraithmayr WM, Korom S, Hillinger S, et al. A mouse model of orthotopic, single-lung transplantation. J Thorac Cardiovasc Surg 2009; 137: 486-491.